Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolism and Pharmacokinetics of [14C]Olodaterol in Healthy Males
NCT02172157Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2008
- Primary completion
- Apr 2008
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of olodaterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Individual time course profiles of [14C]-radioactivity in whole blood, plasma, urine and faeces up to 216 hours, Individual time course profiles of the analyte in plasma and urine up to 216 hours and 11 more. Started Feb 2008; status: completed.
02
Drugs
olodaterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02172157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02172157.